The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience

Haematologica

Volumn 95, Issue 5, 2010, Pages 837-840

  Cimino, Giuseppe ^a   Cenfra, Natalia ^a   Elia, Loredana ^a   Sica, Simona ^b   Luppi, Mario ^c   Meloni, Giovanna ^a   Vignetti, Marco ^a   Paoloni, Francesca ^d   Foà, Robin ^a   Mandelli, Franco ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d GIMEMA Foundation   (Italy)

Author keywords

Acute lymphoblastic leukemia; Adverse prognosis; ALL1(MLL) AF4; Transplant consolidation

Indexed keywords

ALL1 AF4 PROTEIN; ASPARAGINASE; CARCINOGEN; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; HYBRID PROTEIN; MITOXANTRONE; PREDNISONE; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NUCLEAR PROTEINS; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77952309549     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.009035     Document Type: Article

References (22)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-64.
2. Gilliland DG, Tallman MS. Focus on acute leukemias. Cancer Cells. 2002;1(5):417-20.
3. Cimino G, Lo Coco F, Biondi A, Elia L, Luciano A, Croce CM et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood. 1993;82(2):544-6.
4. Tkachuk DC, Kohler S, Cleary ML. Involvement of a homolog of Drosophila trithorax by 11q23 chromosomal translocations in acute leukemias. Cell. 1992; 71(4):691-700
5. Cline MJ. The molecular basis of leukemia. N Engl J Med. 1994;330(5):328-36.
6. McCabe NR, Gill HJ, Espinosa R 3rd, Patel Y, Harden A, et al. Identification of gene, MLL, that spans the breakpoint in 11q23 translocation associated with human leukemias. Proc Natl Acad Sci USA. 1991;88(23):10735-9.
7. Gu Y, Nakamura T, Alder H, Prasad R, Canani O, Cimino G, et al. The t(4,11) chromosome tranlocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell. 1992;71(4):701-8.
8. Djabali M, Selleri L, Parry P, Bower M, Young BD, Evans GA. A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias. Nat Genet. 1992;2(2):113-8
9. Mancini M, Scappaticci D, Cimino G, Nanni M, Derme V, Elia L, et al. A comprehensive genetic classification of adult acute lymphoblasic leukemia (ALL): analysis of the GIMEMA0496 protocol. Blood. 2005; 105(9):3434-41.
10. Cimino G, Elia L, Mancini M, Annino L, Anaclerico B, Fazi P, et al. Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood. 2003;102(6):2014-20.
11. Ludwing WD, Raghavachar A, Thiel E. Immunophenotypic classification of acute lymphoblastic leukemia. Balleres Clin Haematol. 1994;7:235-62.
12. Cimino G, Rapanotti MC, Rivolta A, Lo Coco F, D'Arcangelo E, Rondelli R, et al. Prognostic relevance of ALL1 gene rearrangement in infant acute leukemias. Leukemia. 1995;9(3): 391-5.
13. Annino L, Vegna ML, Camera A, Specchia G, Visani G, Fioritoni G, et al. Treatment of adult lymphoblastic leukemia (ALL): longterm follow-up of the GIMEMA ALL 0288 randomized study. Blood. 2002;99(3):863-71.
14. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposal for the classification of the acute leukaemias: French-AmericanBritish (FAB) cooperative group. Br J Haematol.1976;33(4):351-8.
15. Chomczynsky P, Sacchi N. Single-step method of RNA isolation by acid guanidiu thiocyanatephenol-chloroform extraction. Anal Biochem.1987;162(1):156-9.
16. Biondi A, Rambaldi A, Rossi V, Elia L, Casilini C, Basso G, et al. Detection of ALL1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemia with t(4,11) translocation. Blood. 1993;82(10):2943-7.
17. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, Vance GH, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on Medical Research Council (MRC) UKALL XII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109(8):3189-97.
18. Vey N, Thomas X, Picard C, Kovascovicz T, Charin C, Cayuela JM, et al. Allogenic stem cell transplantation improves the outcome of adults with t(1;19)/E2A-PBX1 and t(4,11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006;20(12):2155-61.
19. Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, et al. Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult prolymphoblastic leukemia: results of German multicenter trials GMALL 03/87 and 04/89. Blood. 1998; 92(6):1898-909
20. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108(5): 1469-77.
21. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24(3):460-6.
22. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007; 109(4):1408-13.